The complex interplay in the regulation of cardiac pathophysiologic functionalities by protein kinases and phosphatases
Chrysanthus Chukwuma Sr*
Published: 26 August, 2021 | Volume 6 - Issue 2 | Pages: 048-054
Protein phosphorylation regulates several dimensions of cell fate and is substantially dysregulated in pathophysiological instances as evident spatiotemporally via intracellular localizations or compartmentalizations with discrete control by specific kinases and phosphatases. Cardiovascular disease manifests as an intricately complex entity presenting as a derangement of the cardiovascular system. Cardiac or heart failure connotes the pathophysiological state in which deficient cardiac output compromises the body burden and requirements. Protein kinases regulate several pathophysiological processes and are emerging targets for drug lead or discovery. The protein kinases are family members of the serine/threonine phosphatases. Protein kinases covalently modify proteins by attaching phosphate groups from ATP to residues of serine, threonine and/or tyrosine. Protein kinases and phosphatases are pivotal in the regulatory mechanisms in the reversible phosphorylation of diverse effectors whereby discrete signaling molecules regulate cardiac excitation and contraction. Protein phosphorylation is critical for the sustenance of cardiac functionalities. The two major contributory ingredients to progressive myocardium derangement are dysregulation of Ca2+ processes and contemporaneous elevated concentrations of reactive oxygen species, ROS. Certain cardiac abnormalities include cardiac myopathy or hypertrophy due to response in untoward haemodynamic demand with concomitant progressive heart failure. The homeostasis or equilibrium between protein kinases and phosphatases influence cardiac morphology and excitability during pathological and physiological processes of the cardiovascular system. Inasmuch as protein kinases regulate numerous dimensions of normal cellular functions, the pathophysiological dysfunctionality of protein kinase signaling pathways undergirds the molecular aspects of several cardiovascular diseases or disorders as related in this study. These have presented protein kinases as essential and potential targets for drug discovery and heart disease therapy.
Read Full Article HTML
Cite this Article
Read Full Article PDF
Oxidative stress; Heart failure; Cardiac hypertrophy; Cardiac myopathy; Serine; Threonine; Ca2+; Spatiotemporal variations
- Chukwuma Sr C. Ecological features of the association between mortality and determinants or salient risk factors of cardiovascular disease. IJCBR. 2020; 6: 18-23.
- Chukwuma Sr C. Ecological attributes between the association of mortality and putative risk factors of cardiovascular disease. IJCBR. 2020; 6: 18-23.
- Chukwuma Sr C. Co-morbid presentations and coronary heart disease risks and type 1 diabetes mellitus. Austin Med Sci. 2019; 4: id1037.
- Chukwuma Sr C. Coexistence of Type 1 diabetes mellitus and risk factors of coronary heart disease. SARJAMS. 2019. SARJAMS_11_25-33.pdf
- Chukwuma Sr C and Tuomilehto J. Type 1 diabetes and the risk of coronary heart disease. Cardiovascular Risk Factors. 1993; 3: 129-137.
- Chukwuma Sr C. Bioinformatics-base and determinants in the spatiotemporal variations of emerging and reemerging infectious diseases. J Ancient Dis Preventive Remedies. 2018; 06.
- Chukwuma Sr C. Regulation of protein-protein interactions in the biosynthetic pathways of bacteria and fungi. 2021.
- Chukwuma Sr C. Presentations of protein-protein-rna interactions in bacteria and fungi. J Bacteriol Mycol.
- Chukwuma Sr C. Features of protein-protein with protein-rna interactions in bacteria and fungi. austinpublishinggroup.com/bacteriology/fulltext/bacteriology/-v6-id1093.pdf
- Singh RM, Cummings E, Pantos C, Singh J. Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev. 2017; 22: 843-859. PubMed: https://pubmed.ncbi.nlm.nih.gov/28702857/
- Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein-kinase signaling pathways: Emerging therapies for cardiovascular disease. Circulation. 2004; 109: 1196-1205. PubMed: https://pubmed.ncbi.nlm.nih.gov/15023894/
- Chukwuma Sr C. Regulation of protein-nucleic acid interactions in biosynthetic pathways of bacteria and fungi: Channels for drug leads. Iatrology Archives. 2020; 1.
- Chukwuma Sr C. Metabolic co-regulation of protein-nucleic acid interactions in fungi and bacteria. MAT Journals. J Advan Pharm Practices. 2020; 1: 41-51.
- Guo DF, Sun YL, Hamet P, Inagami T. The angiotensin II Type 1 receptor and receptor- associated proteins. Cell Res. 2001; 11: 165-180. PubMed: https://pubmed.ncbi.nlm.nih.gov/11642401/
- Lio Y, Chen J, Fontes SK, Bautista EN, Cheng Z. Physiological and pathological roles of protein kinase A in the heart. Cardiovasc Res. 2021; cvab008. PubMed: https://pubmed.ncbi.nlm.nih.gov/33483740/
- Steinberg SE. Mechanisms for redox-regulation of protein kinase G. Front Pharmacol. 2015; 6: 128. PubMed: https://pubmed.ncbi.nlm.nih.gov/26157389/
- Lien CF, Chen SJ, Tsai MC, Lin CS. Potential role of protein kinase C in the pathophysiology of diabetes-associated atheriosclerosis. Front Pharmacol. 2021’ 12: 716332. PubMed: https://pubmed.ncbi.nlm.nih.gov/34276388/
- Marrocco V, Bogomolovas J, Ehler E, G dos Remedios C, Yu J, et al. PKC and PKN in heart disease. J Mol Cell Cardiol. 2019; 128: 212-226. PubMed: https://pubmed.ncbi.nlm.nih.gov/30742812/
- Avkiran M, Rowland AJ, Cuello F and Haworth RS. Protein kinase D in the cardiovascular system. Circ Res. 2008; 102: 157-163. PubMed: https://pubmed.ncbi.nlm.nih.gov/18239146/
- Chukwuma Sr C, Tuomilehto J. Diabetes and the risk of stroke. J Diabetes Complications. 1993; 7: 250-262. PubMed: https://pubmed.ncbi.nlm.nih.gov/8219369/
- Hartmann S, Ridley AJ, Lutz S. The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front Pharmacol. 2015; 6: 276. PubMed: https://pubmed.ncbi.nlm.nih.gov/26635606/
- Boerman M, Fu Q, Wang J, Loose DS, Bartolozzi A, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibotor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis. 2008; 19: 709-718. PubMed: https://pubmed.ncbi.nlm.nih.gov/18832915/
- Weber S, Meyer-Roxlau S, Wagner M, Dobrev D, El-Armouche A. Counteracting protein kinase activity in the heart: The multiple roles of protein phosphatases. Front. Pharmacol. 2015; 6: 270. PubMed: https://pubmed.ncbi.nlm.nih.gov/26617522/
- Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, et al. Effect of the angiotensin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36: 1990-1997. PubMed: https://pubmed.ncbi.nlm.nih.gov/26022006/
- Wieland T, Attwood PV. Alterations in reversible protein histidine phosphorylation as intracellular signals in cardiovascular disease. Front Pharmacol. 2015; 6: 173. PubMed: https://pubmed.ncbi.nlm.nih.gov/26347652/
- Attwood PV. Histidine kinases from bacteria to humans. Biochem. Soc. Trans. 2013; 41: 1023-1028. PubMed: https://pubmed.ncbi.nlm.nih.gov/23863173/
- Ghigo A, Li M. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front Pharmacol. 2015; 6: 169. PubMed: https://pubmed.ncbi.nlm.nih.gov/26321955/
- Braccini L, Ciraolo E, Campa CC, Peri no A, Longo DL, et al. PI3K is a Ra65 effector selectively controlling endosomal AKt2 activation downstream of insulin signalling. Nat Commun. 2015; 6: 7400. PubMed: https://pubmed.ncbi.nlm.nih.gov/26100075/
- Ke Y, Lei M, Solaro RJ. Regulation of cardiac excitation and contraction by p21 activated kinase -1. Prog Biophys Mol Biol. 2009; 98: 238-250.
- Lubbers ER, Mohler PJ. Roles and regulation of protein phosphatase 2A(PP2A) in the heart. J Mol Cell Cardiol. 2016; 101: 127-133. PubMed: https://pubmed.ncbi.nlm.nih.gov/27832939/
- El Refaey M, Musa H, Murphy NP, Lubbers ER, Skaf M, et al. Protein phosphatase 2A regulates cardiac Na+ channels. Circ Res. 2019; 124: 737-746. PubMed: https://pubmed.ncbi.nlm.nih.gov/30602331/
- Cheng J, Valdivia CR, Vaidyanathan R, Balijepalli RC, Ackerman MJ, et al. Cavelin-3 suppresses late sodium current by inhibiting nNOSK-dependent S-nitrosylation of SCN5A. J Mol Cell Cardiol. 2013; 61: 102-110. PubMed: https://pubmed.ncbi.nlm.nih.gov/23541953/
- Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol. 2020; 22: 4124-4135. PubMed: https://pubmed.ncbi.nlm.nih.gov/12024026/
- Prysyazhna O, Eaton P. Redox regulation of cGMP-dependent protein kinase Ia in the cardiovascular system. Front Pharmacol. 2015; 6: 139. PubMed: https://pubmed.ncbi.nlm.nih.gov/26236235/
- Johnston AS, Lehnart SE, Burgoyne TR. Ca2+ signaling in the myocardium by (redox) regulation of PKA/CaMKII. Front Pharmacol. 2015; 6: 166. PubMed: https://pubmed.ncbi.nlm.nih.gov/26321952/
- Brown DI, Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res. 2015; 116; 531-549. PubMed: https://pubmed.ncbi.nlm.nih.gov/25634975/
- Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, et al. Cysteine redox sensors in PKGIa enables oxidation-induced activation. Science. 2007; 317: 1393-1397. PubMed: https://pubmed.ncbi.nlm.nih.gov/17717153/
- Mallova MY, Katus HA, Backs J. Regulation of CaMKII signaling in cardiovascular disease. Front Pharmacol. 2015; 6: 178. PubMed: https://pubmed.ncbi.nlm.nih.gov/26379551/
- Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011; 51: 468-473. PubMed: https://pubmed.ncbi.nlm.nih.gov/21276796/
- Liang Y, Sheikh F. Scaffold proteins regulating extracellular regulated kinase function in cardiac hypertrophy and disease. Front. Pharmacol. 2016; 7: 37. PubMed: https://pubmed.ncbi.nlm.nih.gov/26973524/
- Bernardo BC, Weeks KL, Pretorius L, Mullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010; 128: 191-227. PubMed: https://pubmed.ncbi.nlm.nih.gov/20438756/
- Dorn II GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005; 115: 527-537. PubMed: https://pubmed.ncbi.nlm.nih.gov/15765134/
- Mutlak M, Kehat I. Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy. Front Pharmacol. 2015; 6: 149. PubMed: https://pubmed.ncbi.nlm.nih.gov/26257652/
- Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res. 2011; 108: 176-183. PubMed: https://pubmed.ncbi.nlm.nih.gov/21127295/
- Amin F, Ahmed A, Feroz A, Khaki PSS, Khan MS, et al. An update on the association of protein kinases with cardiovascular disease. Curr Pharm Design. 2019; 25: 174-183. PubMed: https://pubmed.ncbi.nlm.nih.gov/30864507/
- Fischer TH, Eiringhaus J, Dypkova N, Saadatmand A, Pabel S, et al. Activation of protein phosphatase 1 by a selective phosphatase disruptive peptide reduces sarcoplasmic reticulum Ca2+ leak in human heart failure. Eur J Heart Fail. 2018; 20: 1673-1685. PubMed: https://pubmed.ncbi.nlm.nih.gov/30191648/
- DeGrande ST, Little SC, Nixon D, Wright P, Snyder J, et al. Membrane mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J Biol Chem. 2013; 288: 1032-1046. PubMed: https://pubmed.ncbi.nlm.nih.gov/23204520/
- Rapundalo ST. Cardiac protein phosphorylation: functional and pathophysiological correlates. Cardiovasc Res. 1998; 38: 559-588. PubMed: https://pubmed.ncbi.nlm.nih.gov/9747427/
- Yoon S, Kook T, Min HK, Kason DH, Cho YK, et al. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart. Exp Mol Med. 2018; 50: 1-14. PubMed: https://pubmed.ncbi.nlm.nih.gov/30050113/